Jakafi (ruxolitinib) / Incyte, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

128 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jakafi (ruxolitinib) / Incyte
NCT03669965 / 2018-001672-38: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Active, not recruiting
2a/2b
20
Europe, US
KRT-232, Ruxolitinib
Kartos Therapeutics, Inc.
Polycythemia Vera
04/22
10/22
2020-005019-29: Single-arm interventional study with ruxolitinib and AIOEP-BFM2017 chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. Jednoramienne badanie interwencyjne z ruksolitynibem i chemioterapią prowadzoną według protokołu AIOEP-BFM2017 u dzieci z ostrą białaczką limfoblastyczną i potwierdzoną aktywacją ścieżki JAK/STAT.

Not yet recruiting
2
30
Europe
Tablet, Powder for solution for injection/infusion, Solution for injection/infusion, Powder for solution for infusion, Solution for injection, Concentrate for solution for injection/infusion, Powder for solution for injection, Powder, dispersion and solvent for concentrate for dispersion for infusion, Myocet
Medical University of Lodz, Agencja Badań Medycznych
Acute Lymphoblastic Leukemia with confirmed activating of JAK/STAT pathway in children and adolescents <18 years of age Ostra białaczka limfoblastyczna z potwierdzoną sygnaturą molekularną aktywacji szlaku JAK/STAT u dzieci i młodzieży poniżej 18 roku życia, Acute Lymphoblastic Leukemia with confirmed activating of JAK/STAT pathway in children and adolescents <18 years of age Ostra białaczka limfoblastyczna z potwierdzoną sygnaturą molekularną aktywacji szlaku JAK/STAT u dzieci i młodzieży poniżej 18 roku życia, Diseases [C] - Cancer [C04]
 
 
2012-005010-19: Exploring the potential of adding the drug Ruxolitinib to the standard reduced intensity (lower strength) chemotherapy regimen prior to bone marrow transplant in patients with myelofibrosis.

Ongoing
2
86
Europe
Ruxolitinib (INC424), Tablet, Jakavi
Consorzio Mario Negri Sud, National Cancer Institute, Leukaemia & Lymphoma Research
Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF), MF is a form of bone marrow cancer in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring., Diseases [C] - Cancer [C04]
 
 
2011-005279-18: A study of best available therapy versus Ruxolitinib in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide (standard therapy)

Ongoing
2
306
Europe
Ruxolitinib, INC424,
University of Birmingham
Polycythaemia veraEssential Thrombocythaemia
 
 
2012-002253-30: A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm Studio di fase II del Ruxolitinib in pazienti con Trombosi delle Vene Splancniche associata a Neoplasia Mieloproliferativa

Ongoing
2
21
Europe
Jakafy, Jakafy
UNIVERSITA\' DEGLI STUDI DI FIRENZE, Dipartimento di Ematologia dell’Università degli Studi di Firenze
splanchnic vein thrombosis associated with myeloproliferative neoplasm TROMBOSI SPLANCNICA ASSOCIATA A NEOPLASIA MIELOPROLIFERATIVA
 
 
2014-005210-28: Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial Ruxolitinib Behandlung versus allogene Stammzelltransplantation bei Patienten mit Myelofibrose in Abhängigkeit von der Spenderverfügbarkeit

Ongoing
2
155
Europe
allogeneic HSC, allogeneic HSC, Solution for infusion, Tablet, Jakavi
University Medical Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf
primary myelofibrosis primäre Myelofibrose, progressive bone marrow disease (bone marrow cancer) fortschreitende Erkranung des Knochenmarks (Knochenmarkkrebs), Diseases [C] - Cancer [C04]
 
 
2019-003084-21: A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL) STUDIO ACCADEMICO DI FASE-II TESTANTE, IN DUE COORTI PARALLELE NON RANDOMIZZATE, LA COMBINAZIONE DI RUXOLITINIB (INIBITORE DI JAK 1/2) CON BRENTUXIMAB-VEDOTIN O NIVOLUMAB NEL LINFOMA DI HODGKIN CLASSICO RECIDIVANTE O REFRATTARIO (cHL)

Not yet recruiting
2
27
Europe
Ruxolitinib, brentuximab vedotin, Pembrolizumab, [L01XE18], [L01XC12], [NA], Tablet, Powder for solution for infusion, Concentrate for solution for infusion, JAKAVI - 20 MG - COMPRESSA - USO ORALE - BLISTER (PVC/PCTFE/ALU) - 56 COMPRESSE, ADCETRIS - 50 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO, KEYTRUDA - 50 MG- POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO
PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA, Fondi del Dipartimento Medicina
Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento, Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento, Diseases [C] - Cancer [C04]
 
 
2020-001459-42: Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.

Ongoing
2
40
Europe
Tablet, Ruxolitinib (JAKAVI)
Zealand University Hospital, None
COVID-19 PneumoniaSeverly afflicted COVID-19 infected patients in respirator or in the time window with urgent need of respirator before intubation, Severly afflicted COVID-19 infected patients in respirator or in the time window with urgent need of respirator before intubation, Diseases [C] - Virus Diseases [C02]
 
 
2017-005109-11: A study evaluating the impact of Itacitinib alone or when added to ruxolitinib for the treatment of myelofibrosis

Not yet recruiting
2
42
Europe
Itacitinib, INCB039110, Modified-release tablet
Incyte Corporation, Incyte Corporation
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT02638428: Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Recruiting
2
90
RoW
CancerSCAN™, Ifosfamide, Carboplatin, Etoposide, Fludarabine, Cytarabine, Pazopanib, Sorafenib, Axitinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Imatinib, Ruxolitinib, Vandetanib, Vemurafenib, Trastuzumab
Samsung Medical Center, Ministry of Health, Republic of Korea
Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
12/21
12/23
ChiCTR2000029977: Study for Ruxolitinib as a front-line Therapy of pediatric Hemophagocytic Lymphohistiocytosis

Recruiting
2
12
 
5 mg or 10 mg twice daily depending on the body weight (<=20kg or＞20kg, respectively) by oral for 28 days
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, self-raised funds
hemophagocytic lymphohistiocytosis
 
 
NCT03616184: Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Completed
2
49
US
Ruxolitinib
University of Nebraska
Graft-versus-host-disease (GVHD)
01/22
06/23
2021-003227-15: KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis KER-050 come monoterapia o in combinazione con Ruxolitinib in partecipanti con mielofibrosi

Not yet recruiting
2
110
Europe
KER-050, Jakavi, [PRD8997233], [Ruxolitinib], [ruxolitinib], Solution for injection/infusion, Tablet, Jakavi
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelfibrosis (MF)MF- associated cytopenias Myelfibrosis (MF)MF- associated cytopenias, MF is a chronic myeloproliferative malignancy characterized by clonal proliferation of myeloid cells and megakaryocytic hyperplasia/dysplasia resulting in bone marrow fibrosis and osteosclerosis. MF is a chronic myeloproliferative malignancy characterized by clonal proliferation of myeloid cells and megakaryocytic hyperplasia/dysplasia resulting in bone marrow fibrosis and osteosclerosis., Diseases [C] - Cancer [C04]
 
 
REACH5, NCT03774082 / 2018-003296-35: Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Hourglass Oct 2023 - Dec 2023 : Data from REACH5 trial for cGVHD
Completed
2
46
Europe, Canada, Japan, RoW
INC424, Ruxolitinib
Novartis Pharmaceuticals
Graft vs Host Disease
02/22
08/24
REFINE, NCT03222609 / 2017-001398-17: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Data from P2 REFINE trial for myelofibrosis
Dec 2022 - Dec 2022: Data from P2 REFINE trial for myelofibrosis
Checkmark Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Active, not recruiting
2
191
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, Navitoclax, ABT-263
AbbVie
Myelofibrosis (MF)
03/22
01/25
NCT05088226: Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Recruiting
2
50
RoW
Ruxolitinib combined with Chidamide., Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
Chinese PLA General Hospital
Peripheral Blood Stem Cell Transplantation
06/22
06/23
NCT04543279: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Terminated
2
3
US
Fostamatinib, Tavalisse, Ruxolitinib, Jakafi
Washington University School of Medicine, Rigel Pharmaceuticals
Myelofibrosis, Thrombocytopenia
07/22
07/22
ChiCTR2100049996: A single center, prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Ruxolitinib and dexamethasone in the treatment of adult primary hemophagocytic syndrome

Not yet recruiting
2
28
 
Ruxolitinib+dexamethasone
the First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, No
Adult primary hemophagocytic syndrome
 
 
ZGJAK006, NCT04217993: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed
2
51
RoW
Jaktinib hydrochloride tablets, Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
08/22
08/22
NCT03722407: Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Active, not recruiting
2
29
US
Ruxolitinib, Jakafi
H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation
Chronic Myelomonocytic Leukemia, Leukemia
09/22
09/24
NCT04851535: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed
2
34
RoW
Jaktinib Hydrochloride Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelofibrosis
11/22
11/22
NCT03674047: Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Active, not recruiting
2
50
US
ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Other Cancer
12/22
07/24
P30CA015704, NCT02251821: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting
2
61
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, allogeneic stem cell transplantation, HSC, HSCT, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Mycophenolate Mofetil, Cellcept, MMF, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Jakafi, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation, SCT_TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation
Fred Hutchinson Cancer Center, Incyte Corporation, National Cancer Institute (NCI)
Primary Myelofibrosis, Secondary Myelofibrosis
12/22
12/25
NCT02876302: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Active, not recruiting
2
23
US
Ruxolitinib, Jakafi, Paclitaxel, Taxol, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan
Dana-Farber Cancer Institute, Incyte Corporation
Inflammatory Breast Cancer (IBC)
12/22
08/24
ChiCTR2000031702: The role of ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis (HLH) in children

Recruiting
2
200
 
Patients received oral ruxolitinib dosed on 2.5mg, 5 mg or 10 mg twice daily depending on the body weight (≤10kg,≤20kg or＞20kg, respectively)
Beijing Children's Hospital Affiliated to Capital Medical University, National Center for Children's Health; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, self-raised funds
Hemophagocytic lymphohistiocytosis
 
 
NCT04061876: First Line Therapy for High Risk Acute GVHD

Completed
2
198
RoW
Ruxolitinib, New, Corticosteroid, Traditional
Chinese PLA General Hospital, LU DAOPEI MEDICAL, 960th Hospital of PLA, The Second Hospital of Hebei Medical University, The Second Affiliated Hospital of Dalian Medical University, Air Force Military Medical University, China
aGVHD, Stem Cell Transplant Complications
08/22
06/23
LIMBER-213, NCT04821791: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.

Recruiting
2
60
US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
02/23
02/23
PTCyRuxo, NCT04669210: PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT

Active, not recruiting
2
128
RoW
Ruxolitinib, Jakavi, Tacrolimus, Prograf, Mycophenolate Mofetil, CellCept
St. Petersburg State Pavlov Medical University
Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
02/23
02/25
NCT04807777: Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Active, not recruiting
2
3
US
Ruxolitinib, JAKAVI
Columbia University, Incyte Corporation
Advanced Cutaneous Squamous Cell Carcinoma
04/25
05/25
NCT04644211: Ruxolitinib in Thrombocythemia and Polycythemia Vera

Recruiting
2
60
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Essential Thrombocythemia, Polycythemia Vera
12/24
12/24
2020-003123-42: A study evaluating safety, tolerability and efficacy of Itacitinib in participants with primary or secondary Myelofibrosis

Not yet recruiting
2
73
Europe
Itacitinib, INCB039110, Tablet
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Primary Myelofibrosis or Secondary Myelofibrosis, Primary Myelofibrosis or Secondary Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT04629508: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Completed
2
4
Europe, US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
08/23
08/23
NCT03153982: Ruxolitinib in Operable Head and Neck Cancer

Completed
2
16
US
Ruxolitinib, Jakafi
University of California, San Francisco, Incyte Corporation
Head and Neck Squamous Cell Carcinoma
10/23
10/23
NCT06199427: PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Recruiting
2
100
RoW
Cyclophosphamide, Ruxolitinib
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Inborn Errors of Immunity
11/26
12/27
S1712, NCT03654768: Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting
2
84
US
Bosutinib, Bosulif, SKI 606, SKI-606, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Laboratory Biomarker Analysis, Nilotinib, AMN107, NILOTINIB HYDROCHLORIDE MONOHYDRATE, Nilotinib Monohydrochloride Monohydrate, Tasigna, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Imatinib, Gleevec®, STI-571
SWOG Cancer Research Network, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
07/24
07/28
NCT03069326: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Active, not recruiting
2
30
US
Ruxolitinib, Thalidomide
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Celgene, M.D. Anderson Cancer Center
Myelofibrosis
02/25
02/25
NCT06160791: Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Not yet recruiting
2
36
US
Ruxolitinib, INCB18424, Oral JAK, Etoposide, Toposar, Lastet, Dexamethasone, Dexa, Non-interventional Imaging, Ultrasound, Magnetic resonance imaging (MRI), Research Biopsy, Biopsy, Biospecimen Collection, Specimen collection
University of California, San Francisco, Incyte Corporation
Hemophagocytic Lymphohistiocytoses
05/27
05/27
JAKAHDI, NCT06244862: JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

Not yet recruiting
2
42
NA
Ruxolitinib
Assistance Publique - Hôpitaux de Paris
Hemophagocytic Syndromes
08/25
02/26
NCT04218071: Actuate 1901: 9-ING-41 in Myelofibrosis

Completed
2
17
US
Ruxolitinib, Jakafi, 9-ING-41, 9-ING-41 Compound
Actuate Therapeutics Inc.
Myelofibrosis
10/22
01/24
NCT06378060: Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Recruiting
2
30
RoW
Modified transplantation system
Hematology department of the 920th hospital
Severe Aplastic Anemia
04/26
04/27
MPN-RC 119, NCT04281498: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Completed
2
6
Canada, US
Ruxolitinib, Enasidenib
John Mascarenhas, Celgene Corporation, Incyte Corporation, Myeloproliferative Neoplasms Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
05/23
05/23
ChiCTR2100045795: A non-comparative, open, phase II study of ruxolitinib in polycythemia vera subjects who are resistant to or intolerant of hydroxyurea or Interferon alpha

Recruiting
2
60
 
Take ruxolitinib orally
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Novartis Pharma Co., Ltd.
Polycythemia vera (PV)
 
 
NCT03922724: Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Recruiting
2
330
US
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
National Cancer Institute (NCI)
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
06/25
06/29
NCT03427866: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

Active, not recruiting
2
44
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Myelofibrosis
05/24
05/25
NCT06457425: Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial

Recruiting
2
75
RoW
Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib
Chengdu Zenitar Biomedical Technology Co., Ltd
MF,PMF,PPV-MF,PET-MF
05/26
07/26
NCT05413356: Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Recruiting
2
50
RoW
Ruxolitinib, Ruxolitinib twice daily
First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Sir Run Run Shaw Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, The Affiliated People's Hospital of Ningbo University, Jinhua Central Hospital, Taizhou Hospital, Union hospital of Fujian Medical University, Xiangya Hospital of Central South University
Bronchiolitis Obliterans Syndrome, Hematologic Malignancy
06/24
01/25
NCT05600855: Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Recruiting
2
102
RoW
Ruxolitinib
Institute of Hematology & Blood Diseases Hospital
Transplant-Related Disorder
06/24
12/25
NCT05599256: Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Recruiting
2
40
RoW
Ruxolitinib
Institute of Hematology & Blood Diseases Hospital
Transplant-Related Disorder
06/24
12/25
NCT06477549: BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Recruiting
2
220
RoW
Bendamustine Hydrochloride, Ruxolitinib
St. Petersburg State Pavlov Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
06/28
06/29
NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting
2
33
US
Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod
M.D. Anderson Cancer Center, Active Biotech AB
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
05/29
05/31
AURORA, NCT06343792: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Recruiting
2
66
US
RLS-0071
ReAlta Life Sciences, Inc., CTI Clinical Trial and Consulting Services
Steroid Refractory GVHD
04/25
09/25
POTAMI-61, NCT06397313: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Not yet recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
NCT06128070: Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Recruiting
2
40
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Computed Tomography, Chest CT, Computed Tomography of the Chest, Echocardiography, EC, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ruxolitinib Phosphate, INCB-18424 Phosphate, Jakafi, Jakavi, Tacrolimus, FK 506, FK-506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
11/30
11/30
NCT06388564: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Recruiting
2
120
Europe, Canada, US
Axatilimab, Ruxolitinib, Corticosteroids, prednisone, prednisolone, methylprednisolone
Incyte Corporation
Chronic Graft-versus-host-disease
06/27
12/29
NCT02131584: Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
10
US
Questionnaire Administration, Ruxolitinib Phosphate, INCB-18424 Phosphate, Jakafi
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
09/26
09/26
NCT02784496: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Completed
2
8
US
Long-term Follow-up, Quality-of-Life Assessment, Quality of Life Assessment, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myelofibrosis
01/24
01/24
NCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Recruiting
2
200
Europe, Japan, US, RoW
Parsaclisib, INCB050465, parsaclisib + itacitinib, INCB39110, parsaclisib + ruxolitinib, INCB018424, parsaclisib + ibrutinib
Incyte Corporation
B-Cell Malignancies
09/24
09/24
NCT06075225: MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Not yet recruiting
2
62
RoW
Ruxolitinib
Sichuan University
GVHD, Acute Stem Cell Transplant Complications
09/24
09/26
NCT06345495: High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Not yet recruiting
2
30
US
Ruxolitinib, Jakafi, INCB018424, INC424, Allogeneic Stem Cell Transplantation, Autologous stem cell transplant, Cord Blood, Levetiracetam, Eltrombopag, Promacta®, Busulfan, Busulfex™, Myleran®, Romiplostim, AMG 531, Nplate, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®, Mesna, Mesnex™, Tacrolimus, Prograf®
M.D. Anderson Cancer Center, Incyte Corporation
Splenomegaly, Myelofibrosis
01/27
01/29
NCT03333187: Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

Active, not recruiting
2
87
Europe
Allogeneic stem cell transplantation, Ruxolitinib continuous therapy, Jakavi
Universitätsklinikum Hamburg-Eppendorf, Novartis, Clinical Trial Center North (CTC North GmbH & Co. KG)
Bone Marrow Fibrosis
10/24
10/25
NCT02974647: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting
2
82
US
Ruxolitinib
Memorial Sloan Kettering Cancer Center, Cornell University, Dana-Farber Cancer Institute, Thomas Jefferson University
Lymphoma
11/24
11/24
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting
2
25
US
Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518
University of Washington
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
11/26
11/26
ChiCTR2300067517: A single-center, open, single-arm phase II study of ruxolitinib in combination with ACT001 in the treatment of myelofibrosis subjects with poor response to ruxolitinib monotherapy

Not yet recruiting
2
10
 
Oral ACT001 combined with Lucitinib
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
myelofibrosis
 
 
NCT03286530: Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Recruiting
2
64
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Washington University School of Medicine, Vanderbilt University, Ohio State University, Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
12/24
12/26
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
12/24
01/25
NCT02955940: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Active, not recruiting
2
10
Europe, US
Ruxolitinib, INCB018424, Jakafi®, Capecitabine, Xeloda®, Regorafenib, Stivarga®
Incyte Corporation
Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
12/24
12/24
NCT05569538: Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Recruiting
2
40
RoW
Bomedemstat, IMG-7289
The University of Hong Kong, Imago BioSciences,Inc.
Myelofibrosis
12/24
12/25
NCI-2022-02385, NCT05592015: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Recruiting
2
28
US
Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424
John Reneau
T-Cell Large Granular Lymphocyte Leukemia
12/24
12/25
NCT00044304: Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Recruiting
2
60
US
Imatinib, Ruxolitinib
National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
01/25
01/26
NCT03610971: Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors

Recruiting
2
51
NA
Ruxolitinib, Jakafi®, BCR-ABL Tyrosine Kinase Inhibitor (TKI), TKI
H. Lee Moffitt Cancer Center and Research Institute, H. Jean Khoury Cure CML Consortium, Incyte Corporation
Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
01/25
01/25
NCT05817955: Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

Recruiting
2
50
RoW
Azacitidine (AZA) with Ruxolitinib
The First Affiliated Hospital with Nanjing Medical University, Jiangbin Hospital Affiliated to Jiangsu University, Nanjing Second Hospital, Jiangning Hospital Affiliated to Nanjing Medical University
MDS/MPN
01/25
12/26
BIGTIM, NCT06536166: Ruxolitinib Treatment in Inclusion Body Myositis

Not yet recruiting
2
80
NA
Ruxolitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Inclusion Body Myositis, Sporadic
01/28
04/28
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
RESTORE, NCT05037760: Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Dose escalation data from trial for myelofibrosis
Hourglass Jul 2023 - Dec 2023 : Initiation of Part 2 of trial for myelofibrosis
Recruiting
2
110
RoW
KER-050 monotherapy, KER-050 in combination with ruxolitinib
Keros Therapeutics, IQVIA Biotech
Myelofibrosis
04/25
06/25
NCI-2013-00704, NCT01787487: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recruiting
2
125
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Ruxolitinib Phosphate, INCB-18424 Phosphate, Jakafi
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
04/25
04/25
NCT05914714: Ruxolitinib as GVHD Prophylaxis in AA Patients

Not yet recruiting
2
46
NA
Ruxolitinib 5 MG BID Oral Tablet
Institute of Hematology & Blood Diseases Hospital
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
05/25
05/25
ChiCTR2300072481: The efficacy and safety of ruxolitinib in allogeneic hematopoietic stem cell transplantation for GVHD prophylaxis in siblings aged >= 40 years: a multicenter, open, randomized, controlled clinical trial

Recruiting
2
130
 
PT/CY+CSA/FK506+RUX ;ATG+CSA/FK506+MMF+MTX
Henan Cancer Hospital; Henan Cancer Hospital, NA
Hematopoietic setm cell transplantation
 
 
Treg4GVHD, NCT05095649: Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib

Recruiting
2
15
Europe
Regulatory T-cell enriched infusion
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Chronic Graft vs Host Disease
08/25
02/26
NCT04908735: Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

Recruiting
2
40
US
Ruxolitinib
Children's Hospital Medical Center, Cincinnati
Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
11/25
11/25
R-HLH, NCT05762640: Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis

Not yet recruiting
2
20
NA
Ruxolitinib
Assistance Publique - Hôpitaux de Paris
Haemophagocytic Lymphohistiocytosis
11/26
11/27
AALL1521, NCT02723994: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Active, not recruiting
2
171
Canada, US
Ruxolitinib, INCB018424, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Incyte Corporation, Children's Oncology Group
Leukemia
02/26
02/26
NCT03801434: Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Recruiting
2
10
US
Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
William Shomali, Incyte Corporation
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
11/25
11/25
NCT05622318: De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Recruiting
2
56
US
Cyclophosphamide, Cytoxan, Tacrolimus, Astagraf XL, Envarsus XR, Prograf, Mycophenolate Mofetil, CellCept, Ruxolitinib, INC424, Jakafi
Medical College of Wisconsin
Graft-versus-host Disease
12/25
12/25
NCI-2020-01626, NCT04384692: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Recruiting
2
45
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Mycophenolate Mofetil, CellCept, MMF, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Total-Body Irradiation Prior to Stem Cell Transplant, Computed Tomography, CAT Scan, Computed Axial Tomography, Echocardiography, EC, Bone Marrow Aspiration and Biopsy, Magnetic Resonance Imaging, MRI, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging
Fred Hutchinson Cancer Center
Primary Myelofibrosis, Secondary Myelofibrosis
12/25
12/29
NCT05579769: A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Terminated
2
3
US
Ruxolitinib, (Jakafi®), Mesna, (Mesnex), Anti-thymocyte globulin (ATG), (Thymoglobulin®, rabbit ATG), Cyclosporine, (Gengraf), Cyclophosphamide, (Cytoxan), Fludarabine, (Fludara), Methotrexate, Total Body Irradiation (radiation treatment), TBI, Bone marrow infusion, Busulfan, Busulfex), Thiotepa, Triplex by Immunex, TESPA, TSPA
St. Jude Children's Research Hospital
Hematologic Malignancy, Myeloid Malignancy
05/24
05/24
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
Europe, Canada, US
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT05132166: A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease

Active, not recruiting
2
50
Canada
Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
University Health Network, Toronto
Graft Vs Host Disease
04/26
04/26
NCT04640025: A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Active, not recruiting
2
18
Europe, Canada, US, RoW
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
06/26
06/26
BALDER, NCT06075706: Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Recruiting
2
48
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/26
06/31
ChiCTR2400085248: A prospective, single-center, randomized controlled clinical study evaluating the efficacy and safety of ruxolitinib combined with dexamethasone versus HLH-1994 in adult patients with newly diagnosed hemophagocytic lymphohistiocytosis

Not yet recruiting
2
34
 
Ruxolitinib combined with dexamethasone(Ru-D regimen):The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering); HLH-1994 regimen consists of Etoposide (150 mg/m2 twice every week in the first 2 weeks, and weekly in the rest weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering)
The first affiliated hospital Zhejiang University school of medicine; The first affiliated hospital Zhejiang University school of medicine, self-raised funds
hemophagocytic lymphohistiocytosis
 
 
ChiCTR2300071714: A randomized controlled trail of the efficacy and safety of Azacitidine combined with Venetoclax or Ruxolitinib in patients with Ph-myeloproliferative neoplasms in the accelerated/blast phase

Not yet recruiting
2
110
 
Azacitidine + Ruxolitinib + Venetoclax (ARV regimen) ;Azacitidine + Ruxolitinib (AR regimen)
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
myeloproliferative neoplasms
 
 
ChiCTR2400086092: A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of ruxolitinib in combination with P-Gemox in adult patients with newly diagnosed aggressive NK cell leukemia

Not yet recruiting
2
10
 
ruxolitinib 10mg bid D1-21pegaspargase 2500 IU/m2 D2gemcitabine 1000mg/m2 D1,D8oxaliplatin 130mg/m2 D1
The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, self-financing
aggressive NK cell leukemia
 
 
Ruxo-BEAT, NCT02577926: The Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Active, not recruiting
2
207
Europe
Ruxolitinib, Study drug, Jakavi, BAT, Control Treatment
RWTH Aachen University, Novartis Pharmaceuticals
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
12/27
12/28
NCT05398809: Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Recruiting
2
70
US
Ruxolitinib
National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
12/27
12/27
PV, NCT05870475: Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant

Recruiting
2
94
RoW
Ruxolitinib, RUX, Pegylated interferon α-2b, PEG IFNα-2b
Institute of Hematology & Blood Diseases Hospital, China
Polycythemia Vera
03/28
05/28
ChiCTR2400087725: Selinexor combined with luspatercept in transfusion-dependent patients with bone marrow fibrosis-associated anemia refractory or intolerant to ruxolitinib: a prospective, multi-center, phase 2 study

Recruiting
2
40
 
Upon enrollment, subjects will receive the selinexor combined with luspatercept regimen: the standard dose of selinexor is 20mg twice weekly, and will be reduced to 20mg once weekly when platelet counts <30×109/L are observed. The starting dose level of luspatercept is 1.33 mg/kg every 3 weeks and can be increased to the maximum dose level of 1.75 mg/kg every 3 weeks if no response or disappearance of response is observed. Until at least 24 calendar weeks after the first dosing, unless the subject experiences an unacceptable toxic reaction, withdraws informed consent, or meets any other criteria for discontinuation of treatment.
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital with Nanjing, None
bone marrow fibrosis-associated anemia
 
 
NCT04485260 / 2019-004554-29: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Recruiting
1b/2
36
Europe, US, RoW
KRT-232, Ruxolitinib, Jakafi, Jakavi
Kartos Therapeutics, Inc.
Myelofibrosis
10/22
10/24
NCT05280509 / 2021-005724-38: Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Recruiting
1b/2
70
Europe, US
TL-895, Ruxolitinib, Jakafi, Jakavi
Telios Pharma, Inc.
Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
10/25
04/27
ACTRN12621000866808: Evaluating the safety, tolerability and anti-parasitic immunity boosting activity of ruxolitinib when co-administered with artemether-lumefantrine in adults with Plasmodium falciparum Induced Blood Stage Malaria

Recruiting
1/2
26
 
QIMR Berghofer Medical Research Institute, NHMRC Ideas Grant
Malaria
 
 
2016-005214-21: Clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study Ensayo Clínico de ruxolitinib en combinación con nilotinib y prednisona para mielofibrosis: Estudio RuNiC

Ongoing
1/2
44
Europe
Jakavi, prednisone, Tablet, Capsule, Jakavi, Tasigna
Grupo Español de Enfermedades Mieloproliferativas GEMFIN, Grupo Español de Enfermedades Mieloproliferativas Crónicas Filadelfia Negativas, GEMFIN
Myeloproliferative Diseases Enfermedades mieloproliferativas, Myelofibrosis Mielofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
 

Download Options